In a phase 4 trial, dupilumab effectively reduces airway inflammation and mucus plugging, improving lung function and asthma control in patients with moderate to severe type 2 asthma.

Multiple risk factors were associated with denials and longer wait times for biologic treatment in moderate to severe asthma, ...

Dupilumab added to standard COPD triple therapy reduces the annual rate of moderate exacerbations but not severe exacerbations.